Aristea CEO Talks Rare Disease Endpoints And Parallel Fundraising

By Ben Comer, Chief Editor, Life Science Leader

San Diego-based Aristea Therapeutics, spun out of AstraZeneca in 2018 and led by founder, president, and CEO James Mackay, is less than one year away from a clinical trial read-out that could change the company’s trajectory, as well as advance a new drug candidate into late-stage trials for a rare disease with no approved products on the market. With nine employees, Phase 2 trials of lead candidate RIST4721 in multiple conditions, and a uniquely assembled $123 million funding runway, Aristea awaits next year’s Phase 2b trial results in palmoplantar pustulosis (PPP), a rare inflammatory disorder.